Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
68 hedge funds and large institutions have $474M invested in Verona Pharma in 2022 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 6 closing their positions.
483% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 6
288% more capital invested
Capital invested by funds: $122M → $474M (+$352M)
194% more call options, than puts
Call options by funds: $5.57M | Put options by funds: $1.89M
114% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 7
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
70% more funds holding
Funds holding: 40 → 68 (+28)
1.66% more ownership
Funds ownership: 7.27% → 8.93% (+1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$23.8M |
| 2 |
PA
Perceptive Advisors
New York
|
+$18M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$17.7M |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$14.8M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$3.19M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$3.15M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.45M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1.07M |
| 5 |
VP
venBio Partners
San Francisco,
California
|
-$678K |
VRNA Hedge Fund Activity: Q3 2022 in Review
68 of the 5,801 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q3 2022, worth a combined $474M — up 288% from $122M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new VRNA positions and 6 closed out — a net gain of 29 holders — while 15 added to existing stakes and 7 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $23.8M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $3.19M sold.
- 68 institutional investors held Verona Pharma (VRNA) as of Q3 2022, up from 40 in Q2 2022.
- Funds reported $474M of Verona Pharma stock for Q3 2022, up 288% quarter-over-quarter.
- 35 funds opened new Verona Pharma positions in Q3 2022 and 6 closed out, a net change of +29 holders.
- The largest Verona Pharma buyer in Q3 2022 was Deep Track Capital, an estimated $23.8M added.
- The largest Verona Pharma seller in Q3 2022 was Novo Holdings A/S, an estimated $3.19M sold.
Based on aggregated 13F filings for Q3 2022.